Research programme: cystic fibrosis transmembrane conductance regulator modulators - Vertex Pharmaceuticals

Drug Profile

Research programme: cystic fibrosis transmembrane conductance regulator modulators - Vertex Pharmaceuticals

Alternative Names: C-18; CF-106951; CFcor-325; VRT-325; VRT-534

Latest Information Update: 10 Sep 2013

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Piperazines; Quinazolines; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 26 Sep 2012 Preclinical development of VRT-534 is ongoing in USA
  • 30 Jun 2006 Preclinical trials in Cystic fibrosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top